Holen Sie sich die Stockscreener-App
2.07
2.48%
0.05
Handel nachbörslich:
2.06
-0.010
-0.48%
Schlusskurs vom Vortag:
$2.02
Offen:
$2.0202
24-Stunden-Volumen:
61,545
Relative Volume:
2.24
Marktkapitalisierung:
$23.96M
Einnahmen:
$3.02M
Nettoeinkommen (Verlust:
$-653.00K
KGV:
-41.99
EPS:
-0.0493
Netto-Cashflow:
$2.42M
1W Leistung:
-1.43%
1M Leistung:
+3.50%
6M Leistung:
+73.95%
1J Leistung:
+45.26%
1-Tages-Spanne:
$1.985
$2.07
1-Wochen-Bereich:
$1.985
$2.1891
52-Wochen-Spanne:
$0.9811
$2.95
Therapeuticsmd Inc Stock (TXMD) Company Profile
Firmenname
Therapeuticsmd Inc
Sektor
Telefon
561-961-1900
Adresse
951 YAMATO ROAD, SUITE 220, BOCA RATON, FL
Compare TXMD vs TAK, ZTS, TEVA, HLN, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TXMD
Therapeuticsmd Inc
|
2.07 | 23.38M | 3.02M | -653.00K | 2.42M | -0.0493 |
TAK
Takeda Pharmaceutical Co Adr
|
16.55 | 52.32B | 29.85B | 776.90M | 4.35B | 0.2408 |
ZTS
Zoetis Inc
|
112.54 | 47.38B | 9.47B | 2.67B | 2.28B | 6.0218 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
35.86 | 41.16B | 17.53B | 1.58B | 444.18M | 1.3457 |
HLN
Haleon Plc Adr
|
9.17 | 41.02B | 14.54B | 2.22B | 2.58B | 0.4871 |
UTHR
United Therapeutics Corp
|
572.20 | 24.67B | 3.18B | 1.33B | 1.04B | 27.90 |
Therapeuticsmd Inc Stock (TXMD) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-08-07 | Herabstufung | Jefferies | Hold → Underperform |
| 2020-05-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-12-02 | Eingeleitet | Guggenheim | Buy |
| 2019-10-17 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-04-30 | Fortgesetzt | Noble Capital Markets | Outperform |
| 2018-06-15 | Eingeleitet | JP Morgan | Overweight |
| 2017-09-08 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2017-07-11 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2017-05-09 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2016-11-22 | Fortgesetzt | Jefferies | Buy |
| 2016-11-22 | Eingeleitet | Oppenheimer | Outperform |
| 2016-11-07 | Fortgesetzt | Guggenheim | Buy |
| 2016-04-04 | Eingeleitet | Goldman | Buy |
| 2015-12-08 | Bestätigt | Jefferies | Buy |
| 2015-12-08 | Bestätigt | Stifel | Buy |
| 2015-09-21 | Bestätigt | Jefferies | Buy |
| 2015-06-09 | Eingeleitet | Guggenheim | Buy |
| 2014-07-08 | Eingeleitet | FBR Capital | Outperform |
| 2014-04-17 | Bestätigt | Noble Financial | Buy |
| 2014-01-28 | Bestätigt | Noble Financial | Buy |
Alle ansehen
Therapeuticsmd Inc Aktie (TXMD) Neueste Nachrichten
TherapeuticsMD Inc. stock outperforms competitors on strong trading day - MarketWatch
TherapeuticsMD Inc. stock underperforms Monday when compared to competitors - MarketWatch
TherapeuticsMD Inc. stock underperforms Thursday when compared to competitors - MarketWatch
TXMD Should I Buy - Intellectia AI
TXMD (TherapeuticsMD Inc.) posts far wider Q3 2023 loss than expected, with shares dipping 0.48% in today’s trading.Stock Community Signals - Cổng thông tin điện tử tỉnh Tây Ninh
TXMD (TherapeuticsMD Inc.) Q3 2023 EPS misses consensus estimates by wide margin as shares dip 0.48 percent in today's trading.Trending Stock Ideas - Cổng thông tin điện tử tỉnh Tây Ninh
TherapeuticsMD Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
Form 10-K/AAnnual report [Section 13 and 15(d), not S-K Item 405]: [Amend] - ADVFN
Total debt per share of TherapeuticsMD, Inc. – MUN:29TA - TradingView — Track All Markets
TherapeuticsMD Inc. stock rises Wednesday, still underperforms market - MarketWatch
TherapeuticsMD Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
[SCHEDULE 13G] TherapeuticsMD, Inc. Passive Investment Disclosure (>5%) - Stock Titan
Profit Recap: Is TherapeuticsMD Inc stock a buy or sell2026 Review & Real-Time Volume Trigger Notifications - baoquankhu1.vn
TherapeuticsMD Inc. (TXMD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
TherapeuticsMD Inc. R (29TA.F) stock price, news, quote and history - Yahoo Finance UK
TherapeuticsMD Explains Brief Delay In Annual Filing - The Globe and Mail
TherapeuticsMD 2025 Annual Report: Business Overview, Risk Factors, and Intellectual Property Challenges - Minichart
[10-K/A] TherapeuticsMD, Inc. Amends Annual Report - Stock Titan
TherapeuticsMD Inc. stock rises Tuesday, still underperforms market - MarketWatch
TherapeuticsMD, Inc. (TXMD) stock price, news, quote and history - Yahoo Finance UK
TherapeuticsMD Announces Full Year 2025 Financial Results - BioSpace
TherapeuticsMD (NASDAQ: TXMD) files 2025 Form 10-K after printer error - Stock Titan
TherapeuticsMD Narrows 2025 Loss, Advances Royalty Strategy - TipRanks
TXMD Reports $7.5 Million in Cash Holdings as of Year-End 2025 - GuruFocus
TXMD: Net loss narrowed and license revenue surged as strategic alternatives are explored - TradingView
TXMD: 2025 saw improved results from royalty revenue, but litigation and liquidity risks threaten viability - TradingView — Track All Markets
TherapeuticsMD (NASDAQ: TXMD) reports 2025 results, weighs strategic options - Stock Titan
[10-K] TherapeuticsMD, Inc. Files Annual Report - Stock Titan
TXMD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
TherapeuticsMD, Inc. Auditor Raises 'Going Concern' Doubt - marketscreener.com
Lumentum Holdings Leads Six-Month Stock Performance with 425.03% Return - Markets Mojo
TherapeuticsMD Inc. stock underperforms Friday when compared to competitors - MarketWatch
Insider Trends: Whats next for TherapeuticsMD Inc stockQuarterly Portfolio Report & Free Technical Confirmation Trade Alerts - baoquankhu1.vn
Market Overview: Whats next for TherapeuticsMD Inc stockEarnings Growth Summary & Weekly Top Gainers Alerts - baoquankhu1.vn
Lumentum Holdings Leads Stock Performance with 311.87% Return in Six Months - Markets Mojo
If You Invested $1,000 in Therapeuticsmd Inc (TXMD) - Stock Titan
Investment Report: Is TherapeuticsMD Inc forming a double bottom2026 Winners & Losers & High Conviction Buy Zone Alerts - baoquankhu1.vn
Breakout Move: Is TherapeuticsMD Inc stock a falling knife or bargain buy2025 Analyst Calls & Smart Investment Allocation Tips - baoquankhu1.vn
Finanzdaten der Therapeuticsmd Inc-Aktie (TXMD)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.67%
2.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):